Literature DB >> 10375223

Immunoblot analysis of calpastatin degradation: evidence for cleavage by calpain in postmortem muscle.

M E Doumit1, M Koohmaraie.   

Abstract

A negative correlation exists between calpastatin activity and meat tenderness. Therefore, it is important to determine the mechanism of calpastatin inactivation in postmortem skeletal muscle. Western immunoblot analysis was performed to determine the protease(s) responsible for degradation of muscle calpastatin during postmortem storage. To accomplish this, purified calpastatin was digested with different proteases in vitro, and their pattern of calpastatin degradation was compared with that of calpastatin degradation in postmortem muscle. Polyclonal antibodies raised in mice against recombinant bovine skeletal muscle calpastatin were used to monitor calpastatin degradation. Lamb longissimus was stored at 4 degrees C and sampled at 0, 6, 12, 24, 72, 168, and 336 h postmortem. Postmortem storage produced a discrete pattern of calpastatin degradation products that included immunoreactive bands at approximately 100, 80, 65, 54, 32, and 29 kDa. Undegraded calpastatin (130 kDa) was barely detectable after 72 h of postmortem storage at 4 degrees C, and no immunoreactive calpastatin was observed by 336 h postmortem. For in vitro proteolysis, lamb longissimus calpastatin (0 h postmortem) was purified using Affi-Gel Blue chromatography. Calpastatin was digested with m-calpain, mu-calpain, cathepsin B, proteasome, trypsin, or chymotrypsin. Each of these enzymes degraded calpastatin. Immunoreactive fragments resulting from digestion of calpastatin with m- and mu-calpain were similar to each other and closely resembled those observed during postmortem aging of lamb longissimus at 4 degrees C. Digestion of calpastatin with mu-calpain reduced calpastatin activity. Degradation of calpastatin by other proteases resulted in unique patterns of immunoreactive fragments, distinct from that observed in longissimus. Thus, m- and(or) mu-calpain seem to be responsible for calpastatin degradation during postmortem storage of meat.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10375223     DOI: 10.2527/1999.7761467x

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  7 in total

1.  Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.

Authors:  S Sandmann; M Yu; T Unger
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

2.  Leupeptin-based inhibitors do not improve the mdx phenotype.

Authors:  Joshua Selsby; Klara Pendrak; Monica Zadel; Zuozhen Tian; Jennifer Pham; Ted Carver; Pedro Acosta; Elisabeth Barton; H Lee Sweeney
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-09-15       Impact factor: 3.619

3.  Calpain-mediated breakdown of cytoskeletal proteins contributes to cholecystokinin-induced damage of rat pancreatic acini.

Authors:  Heike Weber; Saskia Hühns; Frank Lüthen; Ludwig Jonas
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

4.  Role and differential expression of calpastatin mRNA and protein in cultured cardiomyocytes exposed to hypoxic stress.

Authors:  Huey Lin; Milish P Risbood; Atul Jain; Victor Vacanti; Techung Lee
Journal:  Mol Cell Biochem       Date:  2004-10       Impact factor: 3.396

Review 5.  A New Insight into the Role of Calpains in Post-mortem Meat Tenderization in Domestic Animals: A review.

Authors:  Ting Lian; Linjie Wang; Yiping Liu
Journal:  Asian-Australas J Anim Sci       Date:  2013-03       Impact factor: 2.509

6.  Kihi-to, a herbal traditional medicine, improves Abeta(25-35)-induced memory impairment and losses of neurites and synapses.

Authors:  Chihiro Tohda; Rie Naito; Eri Joyashiki
Journal:  BMC Complement Altern Med       Date:  2008-08-16       Impact factor: 3.659

7.  Are animal models predictive for human postmortem muscle protein degradation?

Authors:  Bianca Ehrenfellner; Angela Zissler; Peter Steinbacher; Fabio C Monticelli; Stefan Pittner
Journal:  Int J Legal Med       Date:  2017-07-18       Impact factor: 2.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.